Cardiac Amyloidosis: Current Diagnostic Strategies Using Multimodality Imaging

Overview

Journal Ann Nucl Cardiol

Date 2023 May 1

PMID 37123486

Authors

Kenji Fukushima

Shintaro Nakano

Ichiro Matsunari

Affiliations

Soon will be listed here.

Abstract

Amyloidosis is a systemic disorder in which abnormal amyloid proteins deposit in body organs, leading to organ dysfunction and death. Cardiac amyloid deposition, causing a sort of restrictive cardiomyopathy and associated with increased risk of mortality. Most cases of cardiac amyloidosis are of either light chain or transthyretin type. Early and accurate diagnosis of cardiac amyloidosis may improve outcomes. However, diagnosis requires systematic approach including electrocardiography and biomarkers when encountered suspicious candidate. Diagnosis by multimodality noninvasive imaging have been substantially studied and established for differentiation from subtypes. Recent advance in the treatment of amyloidosis offers therapeutic monitoring and prognosis.

Citing Articles

2025 Update Consensus of Tc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis from the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.

Wang S, Huang Y, Chen Y, Tsai C, Ko C, Lin Y Acta Cardiol Sin. 2025; 41(1):55-71.

PMID: 39776923 PMC: 11701493. DOI: 10.6515/ACS.202501_41(1).20241027A.

Global and Regional Reduction of Myocardial Perfusion in Patients with Transthyretin Type of Cardiac Amyloidosis: A Dual SPECT Study Using Tc Pyrophosphate and Thallium.

Suenaga H, Fukushima K, Ishii S, Hasegawa O, Muto Y, Yamakuni R Ann Nucl Cardiol. 2024; 10(1):16-22.

PMID: 39635327 PMC: 11612393. DOI: 10.17996/anc.23-00009.

References

Dungu J, Valencia O, Pinney J, Gibbs S, Rowczenio D, Gilbertson J . CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014; 7(2):133-42. DOI: 10.1016/j.jcmg.2013.08.015. View

Fontana M, Banypersad S, Treibel T, Maestrini V, Sado D, White S . Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7(2):157-65. DOI: 10.1016/j.jcmg.2013.10.008. View

Vogelsberg H, Mahrholdt H, Deluigi C, Yilmaz A, Kispert E, Greulich S . Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008; 51(10):1022-30. DOI: 10.1016/j.jacc.2007.10.049. View

Park M, Padera R, Belanger A, Dubey S, Hwang D, Veeranna V . 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study. Circ Cardiovasc Imaging. 2015; 8(8). PMC: 4535193. DOI: 10.1161/CIRCIMAGING.114.002954. View

Dietemann S, Nkoulou R . Amyloid PET imaging in cardiac amyloidosis: a pilot study using F-flutemetamol positron emission tomography. Ann Nucl Med. 2019; 33(8):624-628. DOI: 10.1007/s12149-019-01372-7. View

Pagourelias E, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J . Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. Circ Cardiovasc Imaging. 2017; 10(3):e005588. DOI: 10.1161/CIRCIMAGING.116.005588. View

Awaya T, Minamimoto R, Iwama K, Kubota S, Hotta M, Hirai R . Performance of Tc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy. J Nucl Cardiol. 2019; 27(4):1145-1153. DOI: 10.1007/s12350-019-01868-9. View

Shao J, Rashid S, Renella P, Nguyen K, Hu P . Myocardial T1 mapping for patients with implanted cardiac devices using wideband inversion recovery spoiled gradient echo readout. Magn Reson Med. 2016; 77(4):1495-1504. DOI: 10.1002/mrm.26223. View

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel T, Banypersad S . Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015; 132(16):1570-9. PMC: 4606985. DOI: 10.1161/CIRCULATIONAHA.115.016567. View

10.

Oerlemans M, Rutten K, Minnema M, Raymakers R, Asselbergs F, de Jonge N . Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019; 27(11):525-536. PMC: 6823341. DOI: 10.1007/s12471-019-1299-1. View

11.

Siddiqi O, Sanchorawala V, Ruberg F . Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics. Circ Cardiovasc Imaging. 2018; 11(5):e007826. DOI: 10.1161/CIRCIMAGING.118.007826. View

12.

Rapezzi C, Quarta C, Guidalotti P, Pettinato C, Fanti S, Leone O . Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011; 4(6):659-70. DOI: 10.1016/j.jcmg.2011.03.016. View

13.

Nordberg A, Carter S, Rinne J, Drzezga A, Brooks D, Vandenberghe R . A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012; 40(1):104-14. PMC: 3510420. DOI: 10.1007/s00259-012-2237-2. View

14.

Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I . Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018; 20(1):58. PMC: 6097442. DOI: 10.1186/s12968-018-0478-3. View

15.

Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M . Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. View

16.

Maurer M, Castano A . Prognosticating in Cardiac Amyloidosis: Let Me Count the Ways. JACC Cardiovasc Imaging. 2018; 12(5):834-836. DOI: 10.1016/j.jcmg.2018.04.033. View

17.

Mongeon F, Jerosch-Herold M, Coelho-Filho O, Blankstein R, Falk R, Kwong R . Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012; 5(9):897-907. PMC: 3954504. DOI: 10.1016/j.jcmg.2012.04.006. View

18.

Slart R, Glaudemans A, Hazenberg B, Noordzij W . Imaging cardiac innervation in amyloidosis. J Nucl Cardiol. 2017; 26(1):174-187. PMC: 6394628. DOI: 10.1007/s12350-017-1059-9. View

19.

Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

20.

Austin B, Tang W, Rodriguez E, Tan C, Flamm S, Taylor D . Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 2(12):1369-77. DOI: 10.1016/j.jcmg.2009.08.008. View